Alivus Life Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹588Cr
- +16% YoY
- −2.3% QoQ
- Net profit
- ₹130Cr
- +36.8% YoY
- +6.6% QoQ
- Margin
- 30%
- +3 pp YoY
- +1 pp QoQ
Guidance rank: #71 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.
From Alivus Life's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half.
- Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong.
- Anticipated rebound in GPL business in the second half of FY '26.
- CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up.
- Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually.
- Broad-based growth expected from emerging markets, LATAM, Japan, Europe, and India.
2 more points from Alivus Life's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alivus Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.
- Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25.
- Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay.
- Planned capex spend for H2 FY '26 is around INR250 crores.
- Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track.
- Ankleshwar projects to be operational by June 2026 (Q2 FY '27).
- Dahej projects expected operational from Q1 FY '27.
- Solapur facility targeted to start from April next year.
2 more points from Alivus Life's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Alivus Life's call on order book
Create a free account to keep reading this call
Alivus Life — Quarterly revenue & net profit
Alivus Life Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 588 | 507 | +16% | 602 | -2.3% |
| Operating profit (EBITDA) | 179 | 134 | +33.6% | 172 | +4.1% |
| Operating margin | 30% | 27% | +3 pp | 29% | +1 pp |
| Profit before tax | 174 | 127 | +37% | 163 | +6.7% |
| Net profit (PAT) | 130 | 95 | +36.8% | 122 | +6.6% |
| EPS (₹) | 10.60 | 7.78 | +36.2% | 9.91 | +7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alivus Life and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alivus Life Q2 FY26 results?
The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.
What is Alivus Life share price analysis?
Alivus Life currently shows a neutral. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life planning capital expenditure?
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.
Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
